Brain-computer interface medical devices: China’s innovative registration policy direction

2026-10-10 Healthcare & Pharma / 医药医疗, Patent / 专利, Policy Updates / 政策动态

• At the 2026 International Biomedical Industry Innovation Beijing Forum in Yizhuang, an official from the NMPA Medical Device Registration Management Department said brain-computer interface (BCI) has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is positioned as a future industry.
  在2026国际生物医药产业创新北京论坛（北京亦庄）”神经调控与脑机接口技术产业发展论坛”上，国家药监局医疗器械注册管理司相关负责人表示，脑机接口已被纳入我国”十五五”规划、写入政府工作报告，明确作为未来产业予以布局。

• The regulator signalled that supporting innovative registration and management policies will be introduced to systematically support the development and translation of BCI medical devices.
  药监部门表示将配套创新注册管理政策，系统支持脑机接口医疗器械的研发与落地转化。

• As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings; in 2025 the NMPA approved 14,187 medical-device registrations, up 8 per cent year on year.
  截至2026年7月底，全国有效医疗器械注册备案产品超过34.7万件；2025年国家药监局共批准医疗器械注册14187项，同比增长8%。

• The “Spring Rain Action” clinical-translation programme has collected more than 400 Class III medical-device products and placed 22 quality projects into an expedited pre-review green channel.
  医疗器械临床创新成果转化”春雨行动”已征集400多个三类医疗器械产品，已有22个优质项目纳入审评前置绿色通道。

• On standards, three industry standards for BCI have been issued, ten national standards and three industry standards are under development, and one international-standard proposal has been submitted, covering EEG acquisition, signal transmission, motor-intention decoding and device reliability.
  在标准方面，脑机接口领域已累计发布3项行业标准，立项10项国家标准、3项行业标准，并提交1项国际标准立项提案，覆盖脑电采集、信号传输、运动意图解码与设备可靠性等核心技术环节。

• The regulator describes its approach as “front-loading regulation and standards first”, including pre-application technical guidance for both invasive and non-invasive products and unified naming and classification rules.
  监管方式被概括为”监管前置、标准先行”，包括对多款侵入式、非侵入式产品开展前置技术指导，并统一产品命名与分类界定规则。

• For foreign companies the practical relevance is analytical rather than a formal commitment: the policy direction points to clearer registration pathways, but no specific BCI approval timelines, acceptance numbers or product names have been published.
  对境外企业而言，其实际意义属分析性判断而非官方承诺：政策方向指向更清晰的注册路径，但截至目前并未公布具体的脑机接口审批时限、受理编号或产品名称。

Brain-computer interface medical devices: China’s innovative registration policy direction | 脑机接口医疗器械：中国创新注册管理政策方向

Overview

In October 2026, the 2026 International Biomedical Industry Innovation Beijing Forum was held in Yizhuang, Beijing. At the forum’s “Neuromodulation and Brain-Computer Interface Technology Industry Development Forum”, an official from the Medical Device Registration Management Department of the National Medical Products Administration (NMPA) set out the regulator’s current reading of brain-computer interface (BCI) medical devices and the registration policy direction attached to them.

According to the remarks, BCI has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is expressly positioned as a future industry. On that basis, the regulator said it would put in place supporting innovative registration and management policies to systematically support the research, development and translation of BCI medical devices.

The remarks are a policy-direction statement rather than a new rule. They describe how the existing medical-device registration system is being oriented towards BCI, and they rest on a set of published industry figures that show how the registration base and the innovation-support toolkit have grown.

Key developments

The official’s remarks combined a positioning statement with concrete numbers on China’s medical-device registration landscape.

• Registration base. As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings, spanning Class III registration certificates, Class II registration certificates and Class I filings.
• Annual approvals. In 2025, the NMPA approved 14,187 medical-device registrations, an increase of 8 per cent year on year.
• Clinical translation programme. The “Spring Rain Action” for the translation of clinical innovations in medical devices had collected more than 400 Class III medical-device products, covering high-end tracks such as BCI, interventional surgical robots, AI diagnostic software and high-end interventional implants and biomaterials. 22 quality projects had been placed into an expedited pre-review green channel.

Read together, these figures describe a large and still-growing registration pipeline, and a deliberate effort to move selected high-end products through review faster than the ordinary queue.

Standards first: the pre-review and standards toolkit

Alongside the registration figures, the remarks described the regulator’s operating approach as “front-loading regulation and standards first”.

On standards, the BCI field has seen:

• three industry standards issued;
• ten national standards and three industry standards initiated (立项); and
• one international-standard proposal submitted.

The published standards cover core technical links including EEG acquisition, signal transmission, motor-intention decoding and device reliability.

On regulation, the approach includes:

• advance planning of regulatory-science research;
• pre-application technical guidance for a number of both invasive and non-invasive products; and
• unified rules for product naming and classification.

The “standards first” logic matters for a technology like BCI, where the boundary between a medical device, a consumer wearable and a research instrument can be genuinely unclear. Naming and classification rules, and the existence of standards for core components, are the practical preconditions for a device to move into a defined registration pathway.

Next steps in regulation

The official set out the next steps in general terms: continuing to deepen reform of the medical-device review and approval system and to increase support for high-end innovative devices. Specific measures mentioned included:

• optimising the review mechanism for “globally new” products;
• providing front-loaded services such as clinical-trial pre-review and technical consultation; and
• thereby accelerating the market launch of landmark products.

These are direction statements. They indicate where the regulator intends to concentrate facilitation effort, not the terms on which any individual product will be reviewed.

Practical implications for foreign companies

The following points are analytical observations, not official commitments. They describe what the policy direction may mean for foreign BCI and neurotechnology companies considering the China market.

• The direction of travel is clearer, the details are not. A stated intent to build supporting innovative registration policies for BCI signals that the regulator is treating the field as a priority. It does not, on its own, change any filing requirement, and no BCI-specific approval timeline, acceptance number or product name has been published.
• Classification and naming are the first practical questions. Because the regulator is unifying naming and classification rules for BCI, a company’s early task is to understand how its product would be classified and named under the Chinese system, since that determines the registration pathway.
• Standards participation is a defined channel. With national and industry standards under development and an international-standard proposal submitted, there is an active standards-setting process. Foreign companies commonly monitor or participate in such processes through their China entities or industry associations, though the terms of participation follow the applicable standards rules.
• Patent and intellectual-property positioning deserves early attention. BCI spans hardware, signal-processing algorithms and software. Companies usually review how their patent portfolio maps onto the Chinese classification and standards landscape before committing to a registration strategy. This is a commercial and legal planning point, not a statement of any regulatory preference.
• Translation programmes are a signal, not a guarantee. The “Spring Rain Action” pipeline shows that a subset of high-end products is being routed into an expedited pre-review channel. Being in a high-priority field is relevant context, but selection for such programmes is a separate process.

Related considerations

For a foreign company, the sensible reading of these remarks is as a map of the regulator’s priorities rather than a set of entitlements. The registration figures show scale; the standards activity shows the field maturing towards defined technical requirements; and the “front-loading” language shows where facilitation effort is being directed. A company planning a China BCI strategy would typically combine this policy context with a product-specific review of classification, standards alignment, patent position and the appropriate registration pathway, and would confirm current requirements against the latest official publications before relying on any particular route.

Sources

• 经济参考报 2026-10-08 报道（环球医药网转载）— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
• 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
• 中国网（受权发布）— 《关于发展新质生产力的意见》全文（含”前瞻布局未来产业”等产业定位表述）: https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

脑机接口医疗器械：中国创新注册管理政策方向

概述

2026年10月，2026国际生物医药产业创新北京论坛在北京亦庄举行。在该论坛的”神经调控与脑机接口技术产业发展论坛”上，国家药品监督管理局医疗器械注册管理司相关负责人就脑机接口医疗器械的监管现状与注册政策方向作了介绍。

据该负责人介绍，脑机接口已被纳入我国“十五五”规划、写入政府工作报告，明确作为未来产业予以布局。在此基础上，药监部门表示将配套创新注册管理政策，系统支持脑机接口医疗器械的研发与落地转化。

上述表态属政策方向性说明，而非新出台的规则。它描述的是现行医疗器械注册体系正如何向脑机接口领域倾斜，并以一组已公布的行业数据为依托，展示注册基数与创新支持工具的发展情况。

主要进展

该负责人的介绍将产业定位与具体数据结合在一起，勾勒出我国医疗器械注册的整体面貌。

• 注册基数。 截至2026年7月底，全国有效医疗器械注册备案产品超过34.7万件，涵盖三类注册证、二类注册证及一类备案产品。
• 年度批准量。 2025年，国家药监局共批准医疗器械注册14187项，同比增长8%。
• 临床转化项目。 医疗器械临床创新成果转化“春雨行动”已征集400多个三类医疗器械产品，覆盖脑机接口、介入手术机器人、人工智能诊疗软件、高端植介入生物材料等高端赛道；已有22个优质项目纳入审评前置绿色通道。

综合来看，这组数据一方面说明注册管线规模庞大且仍在增长，另一方面也说明监管机构有意让部分高端产品以快于常规队列的方式通过审评。

标准先行：前置审评与标准工具箱

在注册数据之外，该负责人将监管机构的运行思路概括为“监管前置、标准先行”。

在标准方面，脑机接口领域已实现：

• 累计发布3项行业标准；
• 立项10项国家标准、3项行业标准；
• 提交1项国际标准立项提案。

已发布的标准覆盖脑电采集、信号传输、运动意图解码、设备可靠性等核心技术环节。

在监管方面，相关做法包括：

• 提前布局监管科学研究；
• 对多款侵入式、非侵入式产品开展前置技术指导；
• 统一产品命名与分类界定规则。

“标准先行”的逻辑对脑机接口这类技术尤为重要——医疗器械、消费级可穿戴设备与研究仪器之间的边界有时并不清晰。命名与分类界定规则，以及核心部件标准的建立，是产品得以进入明确注册路径的现实前提。

下一步监管方向

该负责人以总体表述方式提出了下一步方向：持续深化医疗器械审评审批制度改革，持续加大高端创新器械扶持力度。其中提到的具体举措包括：

• 优化”全球新”产品审评机制；
• 提供临床试验预审、技术咨询等前置服务；
• 进而加速标杆产品上市。

这些属方向性表述，指示监管机构拟在何处集中便利化资源，并不等同于任何单一产品的审评条件。

对境外企业的实务意义

以下要点为分析性观察，并非官方承诺。它们描述的是该政策方向对考虑进入中国市场的境外脑机接口与神经技术企业可能意味着什么。

• 方向更清晰，细节尚未明确。 表态提出将为脑机接口构建配套创新注册政策，说明监管机构将该领域视为优先方向。但这一表态本身并不改变任何申报要求，且截至目前并未公布脑机接口专属的审批时限、受理编号或产品名称。
• 分类与命名是首要实务问题。 由于监管机构正在统一脑机接口的命名与分类界定规则，企业的早期工作之一是弄清其产品在中国体系下将被如何分类与命名，因为这决定了注册路径。
• 参与标准化是一条既有通道。 随着国家标准与行业标准在研、国际标准提案已提交，标准化进程处于活跃状态。境外企业通常通过其在华主体或行业协会关注或参与此类进程，但参与条件须遵循适用的标准化管理规定。
• 专利与知识产权布局宜及早关注。 脑机接口横跨硬件、信号处理算法与软件。企业通常会在确定注册策略前，先梳理其专利组合如何对应中国的分类与标准格局。这属商业与法律规划事项，并非监管倾向性表述。
• 转化项目是信号，而非保证。 “春雨行动”管线显示，部分高端产品正被纳入审评前置快速通道。身处高优先级领域是相关背景，但能否入选此类项目是另一套独立程序。

相关考量

对境外企业而言，将上述表态理解为监管机构优先事项的路线图，比理解为一系列既得权益更为妥当。注册数据体现规模，标准化活动体现该领域正走向明确的技术要求，”前置”表述则体现便利化资源投入的方向。规划中国脑机接口战略的企业，通常会将这一政策背景与针对具体产品的分类、标准对齐、专利布局及相应注册路径评估结合起来，并在依赖任何具体路径前，依据最新官方发布确认现行要求。

来源

• 经济参考报 2026-10-08 报道（环球医药网转载）— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
• 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
• 中国网（受权发布）— 《关于发展新质生产力的意见》全文（含”前瞻布局未来产业”等产业定位表述）: https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml